Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Abemaciclib + Lasofoxifene|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Abemaciclib||Verzenio||LY2835219||CDK4/6 Inhibitor 11||Verzenio (abemaciclib) is a dual CDK4/6 inhibitor, which inhibits Rb1 protein phosphorylation and may induce cell cycle arrest and prevent growth in cancer cells (PMID: 24919854). Verzenio (abemaciclib) is FDA approved as a monotherapy and in combination with Faslodex (fulvestrant) in patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative advanced or metastatic breast cancer, in combination with endocrine therapy as adjuvant treatment for patients with hormone receptor-positive (ESR, PGR) and ERBB2 (HER2) receptor-negative, node-positive, early breast cancer at high risk of recurrence and a Ki-67 score equals to or over 20% (FDA.gov).|
|Lasofoxifene||CP 336156|CP-336,156|LAS|Oporia||Hormone - Anti-estrogens 22||Lasofoxifene (CP 336156) is a selective estrogen response modulator (SERM) which binds to estrogen receptors and acts as an antagonist or agonist, and may decrease tumor growth (PMID: 11751385, PMID: 23604900).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04432454||Phase II||Abemaciclib + Lasofoxifene||Evaluation of Lasofoxifene Combined With Abemaciclib in Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation (ELAINEII)||Active, not recruiting||USA||0|